|
Post by joeypotsandpans on Dec 31, 2018 14:12:44 GMT -5
What I've been saying all along - you don't need Technosphere, Dreamboat, or Afrezza's monomer PK/PD to effectively instill insulin nasally for treatment of Alzheimer's. An OTC nasal spray bottle and aerosol insulin will work just fine. I nominate you to the hat trick of MNKD boards, the SAB, BOD, and continued head of PB's...there I've thrown my hat onto the rink for you!! Happy New Year Liane and all ๐๐
|
|
|
Post by joeypotsandpans on Dec 30, 2018 18:04:26 GMT -5
I'm playing poker. The cards I am holding in my hand are terrible. If I give my cards to someone else, they will still be terrible. Most successful poker players I know don't play the cards, they play the other players
|
|
|
Post by joeypotsandpans on Dec 28, 2018 11:40:42 GMT -5
CVI Investments discloses 6.3% passive stake in MannKind CVI Investments reports a 6.3% stake in MannKind, which represents 11.75M shares. The filing does not allow for activism Read more at: thefly.com/landingPageNews.php?id=2841870
|
|
|
Post by joeypotsandpans on Dec 28, 2018 10:10:42 GMT -5
10k of those were me, outside my long position (trading block) ๐
|
|
|
Post by joeypotsandpans on Dec 23, 2018 19:31:30 GMT -5
i wonder if they misspelled the Speaker's last name? i see there is an endocrinologist by the name of Bruce Trippe. The webpage says Bruce Tripp. He's pretty progressive for a 73yr. old endo: "Dr Bruce S. Trippe earned his medical degree from University of Maryland School of Medicine. His internship and residency were completed at Washington Hospital Center in Washington, DC. He completed a combined fellowship in endocrinology at the National Institute of Health and Washington Hospital Center, and then served as chief resident and clinical instructor in internal medicine at George Washington University School of Medicine. Dr Trippe is in private practice in Montgomery, Alabama, and a clinical researcher in diabetes, metabolic weight loss, growth hormone deficiency syndrome, and thyroid cancer research. In addition, he is a national lecturer on the topics of endocrinology and metabolism, and was one of the first lecturers on insulin resistance syndrome (Syndrome X). Dr Trippe is a consultant to major hospitals in South East Alabama, a resident tutor in endocrinology, and a founding member of the American Association of Clinical Endocrinologists. He has been in practice for over 35 years."... Specialties Endocrinology, Diabetes & Metabolism
|
|
|
Post by joeypotsandpans on Dec 21, 2018 15:07:25 GMT -5
"Bears" repeating, I added the plural
|
|
|
Post by joeypotsandpans on Dec 21, 2018 13:14:06 GMT -5
|
|
|
Post by joeypotsandpans on Dec 20, 2018 23:10:30 GMT -5
Today was worse than I anticipated. I figured we'd be hit to about $1.25 to $1.30. Wrong, as usual. Agree - not proportional to the amount of dilution. As usual, the market over reacts. You have to factor in margin calls especially when the broader market is going through steady daily carnage, unfortunately that's the price paid when leveraging with OPM. You can bet there were some involuntary liquidations through the decline.
|
|
|
Post by joeypotsandpans on Dec 20, 2018 13:25:37 GMT -5
After hours is not part of the charts ๐ค๐ง๐ Joey, afrezza is really that good, isn't it?I saw Winston post today. Winston likes afrezza. You all did a good job on the teach. lets just say it seriously never ceases to amaze me, even though we know the PKD behind it when it's your own body and you see the results real time it's truly amazing...for those that can afford it or have the insurance it is worth every penny...I wish all could have access to it, I sincerely sympathize and understand the frustration with those like Alethea. Regarding the cash raise announcement and price action I can only say Mike must of had a very good reason for putting it in motion. I am adding here because it (Afrezza) IS really that good and I still trust Mike to make the decisions necessary to get this company to the next level
|
|
|
Post by joeypotsandpans on Dec 19, 2018 18:27:42 GMT -5
So much for popping out of the wedge. What is it called when you drop 20% in a day? yep. called a failure. MNKD Nasdaq real time volume, ย ย 1,134,209 shares. MNKD Nasdaq summary volume, ย 1,882,866 shares. MNKD Nasdaq after hours volume,ย 228,530 shares.ย MNKD $1.3999 ย -0.3001. ย ย -17.65% After hours is not part of the charts ๐ค๐ง๐
|
|
|
Post by joeypotsandpans on Dec 17, 2018 18:58:46 GMT -5
Goya what I think you are missing is that the new language reflects the stat study results which says the ada is listening to Dr. K. Also this will give docs who read it a reason to prescribe. Key is that Afrezza may lead to less hypos w no additional weight gain. If they were really listening, wouldnโt they actually list a non-inferior insulin treatment, i.e. Afrezza in the SOC along with all other insulin treatments? They treat it as an afterthought, listed below bariatric surgery, ย and that is what ticks me off.ย Block me one one and all.ย Goyo... I empathize with your frustration regarding "SOC", take some solace in knowing it's my SOC, let the delusional naysayers continue to spew their hot air for they know not nor can see their own ignorance. Those that use it can understand why it becomes their SOC and their writers will continue to get it as well, the results of continued improvement in the long term BG numbers and corresponding improved health cannot/will not be denied...the numbers will continue to grow, Sayhey will have his day of reckoning with his exhaustive efforts to educate the ignorant as well, he knows what I mean by that statement, there will be a tipping point ๐
|
|
|
Post by joeypotsandpans on Dec 17, 2018 18:08:23 GMT -5
There is no prandial insulin that comes close to Afrezza, been taking it for a year now, and actually I was one of the scripts in the last report. Had my appt. with endo on the 6th and he sent the script into Express Scripts, same 60/60/60 ct. Happily rec'd at my doorstep last Tues. Talk about holiday cheer ๐ EOM.
|
|
|
Post by joeypotsandpans on Dec 1, 2018 21:57:19 GMT -5
If you are type 1 & pregnant, is it safe to take afrezza? According to Adcomm testimonial speaker #3 Anna Ortiz (around the 8:30 mark) who is T1 and was pregnant during the trial, she is a believer and testified how it made her life easier. youtu.be/ylin1ZSDo0o
|
|
|
Post by joeypotsandpans on Nov 12, 2018 16:04:24 GMT -5
hello, do we all see we are positive while the overall USA stock market is negative? someone is covering slowly. But wait, there's a bus driver and wannabe proxy CEO "and his circle of friends" that claim they know more and are more qualified to run the show. ๐๐๐คฃ
|
|
|
Post by joeypotsandpans on Nov 1, 2018 11:46:20 GMT -5
If that was him, then this is he: www.lakestreetcapitalmarkets.com/Approach/Lake-Street-Team/61"Brooks is a senior research analyst covering high potential but underappreciated healthcare service and device companies. He has spent nearly 30 years in the equity capital markets and investment banking business focused primarily on emerging growth companies. OโNeil was at Piper Jaffray in Minneapolis for 15 years in institutional equity research, sales and investment banking and spent 10 years as a healthcare research analyst at Dougherty & Co. Brooks was recognized by Thomson Reuters Starmine tracking as the No. 1 stock picker out of 65 analysts covering the health services sector twice while at Dougherty. Prior to his career in finance he began his career working in sales and marketing for Procter & Gamble, General Mills and American Express. O'Neil earned a bachelor of arts degree in English from the University of Connecticut and an MBA from The Tuck School at Dartmouth College." He asked a lot of questions and seemed very pleased with Mike's answers. He seemed very positive on Mike & Co. Numero Uno out of 65 analysts covering the health services sector...just the fact that he was on the call should give "some" chills...we know that it has been well no not well but overkill advertised by "some" that the "guidance miss" will not be met well by the street...in fact it has been the mantra of "some" for quite some time. Now you can expect "some" to put their two cents regarding the call and quarterly numbers and pat their egotistical selves about being so prognosticative in their assessments...you know the "I told you so's" that will fall on deaf ears. For those that have followed this story for some time the price action this morning was sooo typical with the shares being sold short only to have it reverse course afterwards on higher volume, after all who in their right mind would be selling from the long side at this point after having weathered the storm of 2016/17? I don't know Brooks but from the looks of things he and others are not showing any disdain for the well advertised "guidance miss". Will be interesting to see if the UTHR agreement has sparked some "pin action" from the analysts that cover it (UTHR) as they look at the next up and comer(s)....#1 out of 65, pretty impressive, let's see if he gets it just like Mr. Pile.
|
|